AbbVie and adMare BioInnovations Foster Life Sciences Innovation with the Launch of the AbbVie Biotech Innovators Award in Quebec

AbbVie and adMare BioInnovations Foster Life Sciences Innovation with the Launch of the AbbVie Biotech Innovators Award in Quebec

  • National competition, in collaboration with adMare BioInnovations, demonstrates AbbVie's commitment to a thriving biotech ecosystem in Quebec
  • One biotech will receive a year of laboratory and office space including access to shared equipment and services at no cost at the adMare Innovation Centre in Montreal, as well as access to AbbVie's scientific and business executives support and mentorship
  • Applications will be accepted until February 20, 2026.

Today, AbbVie (NYSE: ABBV), jointly with the adMare BioInnovations, announced the launch of the AbbVie Biotech Innovators Award, a prize to help foster innovation and support growth in Quebec's life sciences sector.

AbbVie is pleased to collaborate with adMare BioInnovations, an organization dedicated to building strong Canadian life science companies with global impact, to support early-stage biotechnology startup companies with the potential to generate transformational therapies in areas that align with AbbVie's therapeutic areas of focus: immunology, oncology, neuroscience, eye care, and aesthetics.

The award, funded by AbbVie, will provide one early-stage biotech recipient with a year of laboratory and office space including access to shared equipment and services at no cost at the adMare Innovation Centre in Montreal, Quebec. The startup selected will also benefit from AbbVie's scientific and business executives' expertise and counsel to serve as an accelerator of science.

"This award reflects adMare's focus on helping to create and scale globally competitive Canadian life science companies," said Gordon C. McCauley, President and CEO of adMare BioInnovations. We are honoured to partner with AbbVie to provide one of Canada's next biotech leaders with dedicated turn-key wet lab and office space in our Montreal Innovation Centre so that they can build value by focusing on advancing their technology to achieve scientific milestones and ultimately bring life-changing innovation to patients, faster."

"We are delighted to bring this exciting biotech award to researchers in Quebec, highlighting AbbVie's commitment to fostering a thriving life sciences ecosystem and tackling patients' most challenging health issues," said Rami Fayed, Vice President and General Manager of AbbVie Canada. "We look forward to collaborating with adMare BioInnovations and the selected award recipient to help advance meaningful health innovation that will have a remarkable impact on people's lives."

Applications are being accepted from today through February 20, 2026. For more information on the application requirements and judging criteria, or to submit an application, please visit https://www.admarebio.com/en/abbvie-award .

Quebec's vibrant life sciences and health technologies industry contributes $6.5 billion to Quebec's GDP. 1

About AbbVie
AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas – immunology, oncology, neuroscience, and eye care – and products and services in our Allergan Aesthetics portfolio.

For more information about AbbVie, please visit us at www.abbvie.ca . Follow AbbVie Canada on Instagram or find us on LinkedIn .

About adMare BioInnovations
With a strong track record of globally-competitive scientific discovery, Canadian life sciences are primed to lead the world. To make this a reality, adMare BioInnovations uses its scientific and commercial expertise, specialized R&D infrastructure, and seed capital to build strong life sciences companies, develop robust ecosystems, and foster industry-ready talent. It re-invests its returns into the Canadian industry to ensure its long-term sustainability. adMare has helped build 38 companies, of which 27 are still active. These companies have attracted $2.5 billion of risk capital, have a combined value of $5.8 billion, and have created around 1,000 jobs in Canada. Our dynamic Montreal and Vancouver Innovation Centres have been home to 50 life science companies to date, with the 29 current resident companies employing over 400 life sciences professionals. The adMare Academy has trained more than 900 alumni — 87% of whom are employed in the life sciences industry. For more information, please visit www.admarebio.com .

Media Inquiries:

Dominique Touchette Bethany Moir
External Communication Manager Senior Director, Public Affairs
AbbVie Canada adMare BioInnovations
dominique.touchette@abbvie.com bmoir@admarebio.com



1 BIOQuébec. The Voice of the Industry. Available at: https://bioquebec.com/en/


News Provided by GlobeNewswire via QuoteMedia

ABBV
The Conversation (0)
Health Canada Approves AbbVie's RINVOQ®  for the Treatment of Adults with Active Non-Radiographic Axial Spondyloarthritis

Health Canada Approves AbbVie's RINVOQ® for the Treatment of Adults with Active Non-Radiographic Axial Spondyloarthritis

- Approval is based on results from the Phase 3 SELECT-AXIS 2 pivotal clinical trial in which RINVOQ delivered rapid and meaningful disease control, meeting the primary endpoint of ASAS40 response at week 14 versus placebo 1 - RINVOQ is the first and only Janus Kinase (JAK) inhibitor approved to... Keep Reading...
AbbVie Releases New Data Demonstrating Breadth of Its Gastroenterology Portfolio at 2023 Digestive Disease Week®

AbbVie Releases New Data Demonstrating Breadth of Its Gastroenterology Portfolio at 2023 Digestive Disease Week®

- Oral presentations highlight efficacy and safety outcomes from the upadacitinib (RINVOQ ® ) clinical trial program in adults with moderately to severely active Crohn's disease, and investigational use of linaclotide (LINZESS ® ) in treating functional constipation in pediatric patients aged 6... Keep Reading...
Sirona Biochem Announces Exclusive Global Licensing Agreement with Allergan Aesthetics

Sirona Biochem Announces Exclusive Global Licensing Agreement with Allergan Aesthetics

Sirona Biochem Corp . (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (" Sirona ") is pleased to announce it has entered into a global exclusive licensing agreement with Allergan Aesthetics, an AbbVie company (NYSE: ABBV), pursuant to which Allergan Aesthetics will develop and commercialize topical skin... Keep Reading...
InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Compliance

InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Compliance

InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company developing a pipeline of disease-modifying small molecule drug candidates targeting CB1 and CB2 receptors, today announced the Company received a written notice from the Listing Qualifications... Keep Reading...
InMed Pharmaceuticals Announces Positive Data from Human Brain Organoid Neuroinflammation Models Supporting the INM-901 Alzheimer's Disease Program

InMed Pharmaceuticals Announces Positive Data from Human Brain Organoid Neuroinflammation Models Supporting the INM-901 Alzheimer's Disease Program

Human Organoid Data Supports the Therapeutic Rationale for INM-901 Program Ahead of Human Clinical TrialsConsistent Anti-Inflammatory Effects Demonstrate Translation from Animal Models to Three-Dimensional Human Brain Tissue SystemsInMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the... Keep Reading...
SVN-114 selected as the lead candidate for PTSD discovery programme

SVN-114 selected as the lead candidate for PTSD discovery programme

Novel compound from patent-pending SVN-SDN-14 series targeting a major global mental health disorder

Solvonis Therapeutics plc (LSE: SVNS), an emerging biopharmaceutical company developing novel small-molecule therapeutics for high-burden central nervous system ("CNS") disorders, announces the selection of SVN-114 as the lead candidate from the Company's proprietary SVN-SDN-14 discovery... Keep Reading...
InMed Provides Update on Pharmaceutical Development Programs - Advancing Lead Drug Candidates Towards IND and Clinical Trial

InMed Provides Update on Pharmaceutical Development Programs - Advancing Lead Drug Candidates Towards IND and Clinical Trial

Advancing Alzheimer's and Age-Related Macular Degeneration Programs Toward FDA Engagement and IND-Enabling ActivitiesTargeting Initiation of Phase 1 Clinical Trial in Alzheimer's Disease in 2027InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused... Keep Reading...
InMed Provides Update on BayMedica Operations and Strengthens Focus on Pharmaceutical Development Pipeline

InMed Provides Update on BayMedica Operations and Strengthens Focus on Pharmaceutical Development Pipeline

InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of disease-modifying small molecule drug candidates that target CB1CB2 receptors, today announced an update regarding BayMedica LLC ("BayMedica"), a wholly owned... Keep Reading...
Box of Moderna COVID-19 vaccine vials with red caps and labels.

Moderna to Pay US$950 Million to Settle COVID-19 Vaccine Patent Dispute

Moderna (NASDAQ:MRNA) has agreed to pay US$950 million to resolve a long-running patent dispute tied to the technology used in its COVID-19 vaccine.The pharmaceuticals giant announced it has reached a global settlement with Arbutus Biopharma (NASDAQ:ABUS) and Genevant Sciences GmbH over claims... Keep Reading...

Interactive Chart

Latest Press Releases

Related News